Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Free Cash Flow data on record, last reported at -$407.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow changed N/A year-over-year to -$407.0 million; the TTM value through Dec 2025 reached -$540.0 million, changed N/A, while the annual FY2025 figure was -$482.0 million, 183.53% down from the prior year.
  • Free Cash Flow reached -$407.0 million in Q4 2025 per RCUS's latest filing, down from -$133.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $653.0 million in Q1 2022 and bottomed at -$407.0 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$45.3 million, with a median of -$72.0 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: soared 1033.43% in 2022, then tumbled 2116.67% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$83.3 million in 2021, then increased by 13.59% to -$72.0 million in 2022, then dropped by 16.67% to -$84.0 million in 2023, then surged by 129.76% to $25.0 million in 2024, then crashed by 1728.0% to -$407.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$407.0 million in Q4 2025, -$133.0 million in Q1 2025, and $25.0 million in Q3 2024.